Nanolute - Concept Medical
Nanolute
Nanolute

Nanolute Technology

  • Conversion of Sirolimus drug into sub-micron sized particles
  • Nanocarriers created by encapsulation of sub-micron sized
    Sirolimus drug into highly biocompatible drug
    Carrier-phospholipid
  • Upon inflation of MagicTouch SCB at target site, nanocarriers
    with Sirolimus drug inside gets transferred to the vessel wall
    following the principle of co-efficient diffusion
  • Upon body pH variation, nanocarriers mimics the body lipids and
    liberates Sirolimus
  • The sub-micron sized Sirolimus drug particles penetrate the
    deepest layer of the vessel over a period

Challenges Addressed by Nanolute Technology

Improves Lipophilicity of Sirolimus

  • Lipophilicity is the ability of a drug to dissolve in fats, oils, lipids.
  • Sirolimus possess poor lipophilicity and hence require phospholipid.
  • NANOLUTE technology delivers polymer-free nanocarriers containing sirolimus surrounded by encapsulation of a
    proprietary drug carrier, i.e., a phospholipid and improves lipophilicity.

Enhanced Bioavailibility of Sirolimus

  • Bioavailability is a measure of the amount of a drug that reaches the target site.
  • The bioavailability of sirolimus is poor due to higher wash-out rate in the blood stream.
  • The coating of nanocarriers provides very low in-transit drug loss and better drug diffusion, as well as drug retention
    throughout the artery, and penetration of sirolimus to the deep layers of the coronary artery results in enhanced
    bioavailability.

Advantages of Nanolute Technology

  • Facilitates better adhesion of Sirolimus on the balloon surface

    Facilitates better adhesion of Sirolimus on the balloon surface

  • Effective drug transfer to the deepest layer of the vessel

    Effective drug transfer to the deepest layer of the vessel

  • Circumferential coating

    Circumferential coating

  • Better in-tissue bioavailability of Sirolimus

    Better in-tissue bioavailability of Sirolimus

Sirolimus Distribution Study

DTF labelled Sirolimus was used to study the drug distribution following DCB treatment*

A: Adventitia; EEL: External Elastic Lamina; IEL: Internal Elastic Lamina; L:Lumen; M: Media *EuroIntervention. 2013 May 20;9(1): 148-56

Products Designed using Nanolute TECHNOLOGY